Skip to main content

Advertisement

SpringerLink
Log in

The Shifting Paradigm of Treating Neurogenic Bladder Patients After the Introduction of Neuromodulation

  • Overactive Bladder (U Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Over the last 10 years, there have been an increasing number of treatment options for patients with neurogenic bladder. We conducted a literature review of the most current research on mirabegron, onabotulinumtoxin A, sacral nerve modulation (SNM), and posterior tibial nerve stimulation (PTNS) as it pertains to neurogenic bladder. In addition to discussing these treatments, we also discuss how these treatments pertain to the most common etiologies of neurogenic bladder: multiple sclerosis (MS), spinal cord injury (SCI) and Parkinson’s Disease. Each of the above treatment modalities has been shown to be effective in these populations, with the most research behind onabotulinumtoxin A. While SNM and PTNS appear promising, more research is needed with bigger populations to fully elucidate the benefits of these treatments. The decision on which treatment is best for each patient should be individualized based on a patient’s symptoms, disease, and his or her unique preferences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jauarajan K, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep I Urol. 2014;6:1–16.

    Google Scholar 

  2. “BOTOX® (onabotulinumtoxinA) Receives U.S. FDA Approval for the Treatment of Urinary Incontinence in Adults with Neurological Conditions Including Multiple Sclerosis and Spinal Cord Injury”. http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=600958. August, 2011.

  3. FDA approves Botox to treat specific form of urinary incontinence. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269509.htm. August 25, 2011.

  4. Kessler TM, La Framboise L, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58:865–74.

    Article  PubMed  Google Scholar 

  5. Apostolidis A, Dasgupt P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol. 2009;55:100–20.

    Article  CAS  PubMed  Google Scholar 

  6. Zecca C, Digesu GA, Robshaw P, Puccini F, Khullar V, Tubaro A, et al. Motor and Sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice. Eur J Neurol. 2014;21:506–11. Well-constructed study showing PTNS with a 61 % success rate.

    Article  CAS  PubMed  Google Scholar 

  7. Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V. Critical analysis of phase II and III randomized control (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU Int. 2014.

  8. Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomized, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113:951–60.

    Article  CAS  PubMed  Google Scholar 

  9. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind. Placebo-Control Trial Eur Urol. 2011;60:742–50. The largest and most current RCT that discusses only neurogenic patients and botox.

    CAS  Google Scholar 

  10. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnbotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurology etiology. Adv Ther. 2013;30:819–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Sanford M. OnabotulinumtoxinA(Botox): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury. Drugs. 2014.

  12. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized: double blind trial. J Urol. 2011;185:2229–35.

    Article  CAS  PubMed  Google Scholar 

  13. Peters KM, Kandagatia P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.

    Article  PubMed  Google Scholar 

  14. Burks FN, Bui DT, Peters KM. Neuromodulation and the neurogenic bladder. Urol Clin North Am. 2010;37(4):559–65.

    Article  PubMed  Google Scholar 

  15. Gaziev G, Topazio L, Lacovelli V, Asimakopoulos A, Di Santo A, De Nunzio C, et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Amarenco G, Sheikh Ismael S, Even-Schneider A, Raibaut P, Demaille-Wlodyka S, Parratte B, et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003;169:2210–5.

    Article  CAS  PubMed  Google Scholar 

  17. Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. Urology. 2008;71:641–5.

    Article  PubMed  Google Scholar 

  18. Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn. 2009;28:62–7.

    Article  PubMed  Google Scholar 

  19. Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicenter prospective open label trial. Mult Scler J. 2011;17(12):1514–9.

    Article  CAS  Google Scholar 

  20. Sand PK, Sand RI. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis. Dis Month. 2013;59:261–8.

    Article  Google Scholar 

  21. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184:1011–6.

    Article  CAS  PubMed  Google Scholar 

  22. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9. A double-blind RCT with large population that follows QOL and urodynamic changes of patients with neurologic detrusor overactivity after botox injection.

    Article  CAS  PubMed  Google Scholar 

  23. Schurch B, Carda S. OnbotulinumtoxinA and multiple sclerosis. Ann Phys Rehab Med. 2014;57:302–14.

    Article  CAS  Google Scholar 

  24. Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-a for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344–9.

    Article  CAS  PubMed  Google Scholar 

  25. Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30:123–8. A good study that is specific to MS patients who underwent SNM.

    Article  PubMed  Google Scholar 

  26. Marinkovic SP, Gillen LM. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J. 2010;21:223–8.

    Article  PubMed  Google Scholar 

  27. Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label multicenter. Prospect Stud J Urol. 2014;191:697–702. Prospective study specific to patients with multiple sclerosis, this does not have urodynamic findings.

    CAS  Google Scholar 

  28. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:191–6.

    Google Scholar 

  29. Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil. 2005;86(11):2114–8.

    Article  PubMed  Google Scholar 

  30. Schurch B, Stoher M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Prelim Results J Urol. 2000;164:692–7.

    Article  CAS  Google Scholar 

  31. Chen SF, Kuo HC. Therapeutic outcome and patient adherence to repeated onabotulinumtoxin A detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity. J Formos Med Assoc. 2013;20:1–7. A Prospective trial that quantifies the effect of botox on SCI patients both with urodynamic findings and symptom improvement.

    Google Scholar 

  32. Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord. 2009;47:486–91.

    Article  CAS  PubMed  Google Scholar 

  33. Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten year follow up single-centre experience. Spinal Cord. 2014;52:241–5.

    Article  CAS  PubMed  Google Scholar 

  34. Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanism, prevalence. Symptom Manage Mov Disord. 2006;21:737–46.

    Article  Google Scholar 

  35. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186:960–4.

    Article  CAS  PubMed  Google Scholar 

  36. Anderson RU, Orenerg EK, Glow P. Onabotulinumtoxin A office treatment for neurogenic bladder incontinence in Parkinson’s disease. Urology. 2014;83(1):22–7. Prospective trial that is very current and specific to the Parkinson’s population.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Patrick Kilday, George A. Abdelsayed, and Polina Reyblat declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Kaiser Permanente Southern California, 4900 Sunset Blvd, Second Floor, Los Angeles, CA, 90027, USA

    Patrick Kilday, George A. Abdelsayed & Polina Reyblat

Authors
  1. Patrick Kilday
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Abdelsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Polina Reyblat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Kilday.

Additional information

This article is part of the Topical Collection on Overactive Bladder

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kilday, P., Abdelsayed, G.A. & Reyblat, P. The Shifting Paradigm of Treating Neurogenic Bladder Patients After the Introduction of Neuromodulation. Curr Bladder Dysfunct Rep 10, 6–13 (2015). https://doi.org/10.1007/s11884-014-0282-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-014-0282-3

Keywords

Search

Navigation